Jensen J Eric, Daniels Melissa, Haws Charlotte, Bolo Nicolas R, Lyoo In Kyoon, Yoon Sujung J, Cohen Bruce M, Stoll Andrew L, Rusche James R, Renshaw Perry F
Brain Imaging Center, McLean Hospital, Belmont, Massachusetts 02478-9106, USA.
Exp Clin Psychopharmacol. 2008 Jun;16(3):199-206. doi: 10.1037/1064-1297.16.3.199.
Eleven patients with bipolar depression were given doses of up to 18 g per day of triacetyluridine (TAU) over 6 weeks to test the effect of uridine on symptoms of depression via Montgomery-Asberg Depression Rating Scale (MADRS; Asberg, Montgomery, Perris, Schalling, & Sedvall, 1978) scores and on cellular bioenergetics using phosphorus magnetic resonance spectroscopic imaging (31P-MRSI). All patients and comparison participants (n = 9) completed baseline 31P-MRSI scans, and 9 patients completed posttherapy scans. The percentage changes for MADRS scores (Week 2, -23.8; Week 3, -34.9; Week 4, -42.5) and the time effects of TAU on MADRS scores (Week 2, z = -2.07, p = .039; Week 3, z = -4.28, p < .001; Week 4, z = -4.54, p < .001) may reflect TAU effects on early symptom improvement. TAU responders (patients who had a 50% or greater reduction in MADRS scores from baseline at any time) demonstrated a significant difference from nonresponders in pH changes from baseline (effect size = 150). These results suggest that TAU treatment may decrease symptoms of depression and improve mitochondrial functioning.
11名双相抑郁症患者在6周内每天服用高达18克的三乙酰尿苷（TAU），以通过蒙哥马利-阿斯伯格抑郁评定量表（MADRS；阿斯伯格、蒙哥马利、佩里斯、沙林和塞德瓦尔，1978年）评分来测试尿苷对抑郁症状的影响，并使用磷磁共振波谱成像（31P-MRSI）来测试其对细胞生物能量学的影响。所有患者和对照参与者（n = 9）均完成了基线31P-MRSI扫描，9名患者完成了治疗后扫描。MADRS评分的百分比变化（第2周，-23.8；第3周，-34.9；第4周，-42.5）以及TAU对MADRS评分的时间效应（第2周，z = -2.07，p = .039；第3周，z = -4.28，p < .001；第4周，z = -4.54，p < .001）可能反映了TAU对早期症状改善的影响。TAU反应者（在任何时间MADRS评分较基线降低50%或更多的患者）与无反应者相比，pH值从基线的变化存在显著差异（效应大小 = 150）。这些结果表明，TAU治疗可能会减轻抑郁症状并改善线粒体功能。
